Adicet Bio Inc at Jefferies Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Terrific. Maybe about the data update in Q2. Could you provide some details regarding as to what venue and how many patients of data will be included? And also will there be a KOL event?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : I see. Just to confirm, you mentioned, we're going to hear active feedback regarding the trial design. So I may ask has this meeting conducted yet?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Okay. Terrific. And I think in the past you also have mentioned in the post CD19 CAR T settings, there could be a potential, faster regulatory path? And can you talk about a potential trial design?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Okay, great. Thank you for sharing this. So I think the point here is just simply compare the short-term CR rate between bispecifics versus other cell therapies is probably not the best approach. Durable CR is probably the key we should focused on? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 08, 2023 / 2:30PM, ACET.OQ - Adicet Bio Inc at Jefferies Healthcare Conference

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Okay, well taken. And a relevant question here is let's just focus on the cell therapy for the moment and also ADI-001. What do you think about the regulatory bar in the post-CD19 CAR T settings regarding OR, CR, and also durable CR assuming at six months? Could you put a number on that?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Let me ask an alternative question. There are other autologous cell therapy programs ongoing in the post-CD19 settings. For ADI-001, should we expect a similar efficacy performance to those autologous programs?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Great. And so still for the data update in Q2, could you actually share what the percentage of the patients actually treated in the post-CD19 settings? Although this is the priority, but I'm also curious for the CD19 naive patients, how many have been treated and how much of the data you could share for the Q2 update?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Okay. How about the dose level? Could you -- I think not all the investors are fully clear about how many doses you're working on, and also some nuance about the dosing schedule. Can you actually reiterate the ongoing trials?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Great. Looking forward to your future update. Maybe change the topic a little bit to the CAd programs. You recently elaborated during R&D day. And can you also talk about what is the rationale of using CAd gamma-delta T cells? And what are the most attractive advantages of using this technology?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Okay, great. Maybe also, given that there are not too much of a clinical data based on gamma-delta T cells out there, so curious, based on preclinical research and also maybe translational research ongoing at Adicet, what are the most compelling evidence that gamma-delta T cells could be very durable?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Okay, great. And can you also give us an update on the development of ADI-002?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : And what is your cash position, cash runway? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 08, 2023 / 2:30PM, ACET.OQ - Adicet Bio Inc at Jefferies Healthcare Conference

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : And lastly, can you lay down the company's plan for 2023 and 2024, and what investors should look forward in the next 24 months?

Question: Kelly Shi - Jefferies & Company, Inc. - Analyst : Great. Thank you for sharing this. And we will wrap up here. And thanks, everyone, for attending. And thanks, Chen.